Statistics on CRM available in this Spotlight do not reflect the impact of COVID-19 on cardiac rhythm management procedures, which include implants of devices designed to regulate the beating of the heart. These include implantable defibrillators and pacemakers. Financial reports from the largest providers of these devices—Medtronic, Boston Scientific, and Abbott – indicate that sales of these segments in the second quarter of 2020 were down between 30% and 40% compared to a similar period in 2019.
Although there was a drastic decrease in volume in CRM procedures in Q2/2020, the shares, average selling prices, and trends between 2018 and 2019 reported here will likely be reflected in the 2020 data available sometime next year. Download the spotlight to access more CRM trends.